AR034158A1 - Derivados de 1-aminobutano-3-ol sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de derivados de 1-aminobutano-3-ol sustituidos para la preparacion de medicamentos - Google Patents
Derivados de 1-aminobutano-3-ol sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de derivados de 1-aminobutano-3-ol sustituidos para la preparacion de medicamentosInfo
- Publication number
- AR034158A1 AR034158A1 ARP010104583A ARP010104583A AR034158A1 AR 034158 A1 AR034158 A1 AR 034158A1 AR P010104583 A ARP010104583 A AR P010104583A AR P010104583 A ARP010104583 A AR P010104583A AR 034158 A1 AR034158 A1 AR 034158A1
- Authority
- AR
- Argentina
- Prior art keywords
- polysubstituted
- mono
- unsubstituted
- unsaturated
- saturated
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- NAXUFNXWXFZVSI-UHFFFAOYSA-N 4-aminobutan-2-ol Chemical group CC(O)CCN NAXUFNXWXFZVSI-UHFFFAOYSA-N 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 23
- 125000003118 aryl group Chemical group 0.000 abstract 13
- 125000001072 heteroaryl group Chemical group 0.000 abstract 12
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 7
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 5
- 208000004454 Hyperalgesia Diseases 0.000 abstract 5
- 208000002193 Pain Diseases 0.000 abstract 5
- 230000036407 pain Effects 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 150000007513 acids Chemical class 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 206010015037 epilepsy Diseases 0.000 abstract 2
- 208000004296 neuralgia Diseases 0.000 abstract 2
- 230000002981 neuropathic effect Effects 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000035154 Hyperesthesia Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- 208000004550 Postoperative Pain Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 206010041415 Spastic paralysis Diseases 0.000 abstract 1
- 150000008043 acidic salts Chemical class 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 150000001447 alkali salts Chemical class 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 206010053552 allodynia Diseases 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 230000001773 anti-convulsant effect Effects 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000011384 erythromelalgia Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 231100001014 gastrointestinal tract lesion Toxicity 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 206010029864 nystagmus Diseases 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
Derivados de 1-aminobutano-3-ol sustituido, de la fórmula general (1), en la cual: R1 y R2 representan independientemente entre sí alquilo C1-6 de cadena recta o ramificada, saturado o insaturado, no sustituido o mono o polisustituido, o R1 y R2 representan conjuntamente un ciclo (CH2)2-9, eventualmente sustituido con alquilo C1-8, de cadena recta o ramificada, saturado o insaturado, no sustituido o mono o polisustituido, o arilo no sustituido o mono o polisustituido; R3 y R4 representan independientemente entre sí alquilo C1-6, saturado o insaturado, ramificado o no ramificado, no sustituido o mono o polisustituido, cicloalquilo C3-6 saturado o insaturado, no sustituido o mono o polisustituido, fenilo, bencilo o fenetilo, no sustituidos o mono o polisustituidos, o R3 y R4 en conjunto forman un ciclo y representan (CH2)3-6 ó CH2CH2OCH2CH2; R5 representa alquilo C1-10 saturado o insaturado, ramificado o no ramificado, no sustituido o mono o polisustituido, cicloalquilo C3-9 saturado o insaturado, arilo o heteroarilo, arilo ligado a través de alquilo C1-3 saturado o no saturado, cicloalquilo C3-10 ligado a través de alquilo C1-3 saturado o no saturado, o heteroarilo ligado a través de alquilo C1-3 saturado o no saturado, en donde todos los radicales arilo, heteroarilo y cicloalquilo pueden ser no sustituidos o mono o polisustituidos con sustituyentes elegidos independientemente entre sí entre F, Cl, Br, I, OR18, SR18, SO2R18, SO2OR18, CN, COOR18, NR19R20, alquilo C1-10 saturado o insaturado, ramificado o no ramificado, no sustituido o mono o polisustituido, cicloalquilo C3-9 saturado o insaturado, no sustituido o mono o polisustituido, arilo o heteroarilo, no sustituido o mono o polisustituido, arilo ligado a través de alquilo C1-3 saturado o no saturado, cicloalquilo C3-9 o heteroarilo ligado a través de alquilo C1-3 saturado o no saturado, no sustituido o mono o polisustituido; R18 representa H, alquilo C1-10 saturado o insaturado, ramificado o no ramificado, no sustituido o mono o polisustituido, cicloalquilo C3-9 saturado o insaturado, no sustituido o mono o polisustituido, arilo o heteroarilo, no sustituido o mono o polisustituido, arilo, cicloalquilo C3-9 o heteroarilo ligado a través de alquilo C1-3 saturado o no saturado, no sustituido o mono o polisustituido; R19 y R20 representan independientemente entre sí H, alquilo C1-10 saturado o insaturado, ramificado o no ramificado, no sustituido o mono o polisustituido, cicloalquilo C3-9 saturado o insaturado, no sustituido o mono o polisustituido, arilo o heteroarilo, no sustituido o mono o polisustituido, arilo, cicloalquilo C3-9 o heteroarilo, ligado a través de alquilo C1-3 saturado o no saturado, no sustituido o mono o polisustituido, o R19 y R20 en conjunto representan CH2CH2OCH2CH2, CH2CH2NR21CH2CH2 ó (CH2)3-6; R21 representa H, alquilo C1-10 saturado o insaturado, ramificado o no ramificado, no sustituido o mono o polisustituido; R6 representa H, arilo o heteroarilo, no sustituidos o mono o polisustituidos; y R7 representa halógeno, CF3, alquilo C1-6 saturado o insaturado, ramificado o no ramificado, no sustituido o mono o polisustituido, cicloalquilo C3-9 saturado o insaturado, no sustituido o mono o polisustituido, arilo o heteroarilo, no sustituido o mono o polisustituido, arilo, cicloalquilo C3-9 o heteroarilo, ligados a través de alquilo C1-3 saturado o no saturado, no sustituido o mono o polisustituido; en forma de sus racematos, enantiómeros, diastereómeros, particularmente mezclas de sus enantiómeros o diastereómeros o un enantiómero o diastereómero o enantiómero individual; en forma de sus sales ácidas o básicas o sales con cationes o bases o con aniones o ácidos fisiológicamente tolerables, o en forma de sus ácidos o bases libres, procedimiento para su preparación, medicamentos que contienen estos compuestos y su uso para la preparación de medicamentos, para el tratamiento de dolores, particularmente dolores neuropáticos, crónicos o agudos, para el tratamiento de migranas, hiperalgesia y alodinia, particularmente hiperalgesia térmica, hiperalgesia mecánica, alodinia y crioalodinia o de dolores inflamatorios o postoperatorios, para el tratamiento de epilepsia, calores y otros desórdenes postmenopáusicos, esclerosis lateral amiotrofica (ALS), distrofia simpática refleja (RSD), parálisis espástica, síndrome de las piernas inquietas, nistagmo adquirido, afecciones psiquiátricas o neuropatológicas, tales como perturbaciones bipolares, ansiedad, ataques de pánico, modificaciones de carácter, comportamiento maníaco, depresiones, comportamiento maniaco-depresivo, neuropatía diabética dolorosa, síntomas y dolores resultantes de esclerosis múltiple o enfermedad de Parkinson, enfermedades neurodegenerativas tales como enfermedad de Alzheimer, enfermedad de Huntington, enfermedad de Parkinson y epilepsia, lesiones gastrointestinales; dolores eritromelalgicos o postoliomieliticos, neuralgia del trigémino o postherpetica, o como anticonvulsivo, analgésico o ansiolitico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10049483A DE10049483A1 (de) | 2000-09-29 | 2000-09-29 | Substituierte 1-Aminobutan-3-ol-Derivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034158A1 true AR034158A1 (es) | 2004-02-04 |
Family
ID=7658871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104583A AR034158A1 (es) | 2000-09-29 | 2001-09-28 | Derivados de 1-aminobutano-3-ol sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de derivados de 1-aminobutano-3-ol sustituidos para la preparacion de medicamentos |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US7022739B2 (es) |
| EP (2) | EP1322592B2 (es) |
| JP (2) | JP2004509939A (es) |
| KR (2) | KR100835549B1 (es) |
| CN (2) | CN1478067A (es) |
| AR (1) | AR034158A1 (es) |
| AT (2) | ATE272045T1 (es) |
| AU (4) | AU2001289937B2 (es) |
| BR (2) | BR0114381A (es) |
| CA (2) | CA2423903A1 (es) |
| DE (3) | DE10049483A1 (es) |
| DK (2) | DK1322593T3 (es) |
| EC (2) | ECSP034530A (es) |
| ES (2) | ES2225605T5 (es) |
| HK (2) | HK1052925B (es) |
| HU (2) | HUP0303361A3 (es) |
| IL (2) | IL155105A0 (es) |
| MX (2) | MXPA03002737A (es) |
| NO (2) | NO20031387L (es) |
| NZ (2) | NZ524976A (es) |
| PE (1) | PE20020413A1 (es) |
| PL (2) | PL361382A1 (es) |
| PT (2) | PT1322593E (es) |
| RU (2) | RU2288219C2 (es) |
| SI (2) | SI1322592T1 (es) |
| SK (2) | SK3382003A3 (es) |
| TR (2) | TR200402030T4 (es) |
| WO (2) | WO2002028817A1 (es) |
| ZA (2) | ZA200303220B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10049483A1 (de) * | 2000-09-29 | 2002-05-02 | Gruenenthal Gmbh | Substituierte 1-Aminobutan-3-ol-Derivate |
| AU2002337863B2 (en) | 2001-10-16 | 2007-10-11 | Endo Pharmaceuticals Inc. | Carbinols for the treatment of neuropathic dysfunction |
| WO2003059880A1 (en) * | 2002-01-11 | 2003-07-24 | Sankyo Company, Limited | Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these |
| US8128957B1 (en) | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
| US20050182056A9 (en) * | 2002-02-21 | 2005-08-18 | Seth Pawan | Modified release formulations of at least one form of tramadol |
| ATE465726T1 (de) | 2002-11-22 | 2010-05-15 | Gruenenthal Gmbh | Verwendung von (1r, 2r)-3-(3-dimenthylamino-1- ethyl-2-methyl-propyl)-phenol zur behandlung von entzündungsschmerz |
| US7910617B2 (en) | 2004-02-24 | 2011-03-22 | Sankyo Company, Limited | Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound |
| CN103936605B (zh) * | 2007-05-31 | 2017-09-01 | 赛诺维信制药公司 | 苯基取代的环烷胺作为一元胺再摄取抑制剂 |
| MX2011005788A (es) * | 2008-12-05 | 2011-06-21 | Arqule Inc | Inhibidores raf y sus usos. |
| ES2343050B1 (es) * | 2008-12-16 | 2011-06-14 | Chemo Iberica, S.A. | Procedimiento para la preparacion de desvenlafaxina y sus sales de adicion de acido farmaceuticamente aceptables. |
| WO2012100423A1 (en) * | 2011-01-27 | 2012-08-02 | Eli Lilly And Company | Analgesic compounds, methods, and formulations |
| JP2019502761A (ja) * | 2016-01-21 | 2019-01-31 | ラボラトリオス レヴィ エセエレ | （（ｒ）−３−［（−１−メチルピロリジン−２−イル）メチル］−５−（２−フェニルスルホニルエチル）−１ｈ−インドールを作製する方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3652589A (en) * | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
| ZA732238B (en) * | 1972-04-06 | 1974-01-30 | American Home Prod | Benzylamine analgesics |
| US4155935A (en) * | 1973-03-26 | 1979-05-22 | American Home Products Corporation | Benzylamine analgesics |
| DE19525137C2 (de) * | 1995-07-11 | 2003-02-27 | Gruenenthal Gmbh | 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe |
| US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| DE19547766A1 (de) | 1995-12-20 | 1997-06-26 | Gruenenthal Gmbh | 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-verbindungen als pharmazeutische Wirkstoffe |
| DE19601744C2 (de) * | 1996-01-19 | 1998-04-16 | Gruenenthal Gmbh | Verfahren zur Herstellung der Enantiomeren von O-Demethyltramadol |
| DE19609847A1 (de) * | 1996-03-13 | 1997-09-18 | Gruenenthal Gmbh | Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe |
| US5919826A (en) * | 1996-10-24 | 1999-07-06 | Algos Pharmaceutical Corporation | Method of alleviating pain |
| US6245804B1 (en) * | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
| EP0996613B1 (en) * | 1997-07-15 | 2002-10-30 | Russinsky Limited | Pure cis-tramadol hydrochloride production |
| EP1077923B1 (en) * | 1998-05-22 | 2004-01-02 | Mallinckrodt Inc. | An improved synthesis and purification of (r*,r*)-2- (dimethylamino) methyl]-1-( 3-methoxyphenyl) cyclohexanol hydrochloride |
| ES2141688B1 (es) * | 1998-11-06 | 2001-02-01 | Vita Invest Sa | Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos. |
| DE19915601A1 (de) * | 1999-04-07 | 2000-10-19 | Gruenenthal Gmbh | 3-Amino-3-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung |
| MXPA02001820A (es) * | 1999-08-20 | 2003-07-14 | Johnson & Johnson | Composicion que comprende un material de tramadol y un farmaco anticonvulsivo. |
| PE20010623A1 (es) * | 1999-10-05 | 2001-07-07 | Gruenenthal Chemie | Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria |
| US6339105B1 (en) * | 1999-10-12 | 2002-01-15 | Ortho-Mcneil Pharmaceutical, Inc. | Analgesic regimen |
| DE10000312A1 (de) * | 2000-01-05 | 2001-07-12 | Gruenenthal Gmbh | Substituierte Aminomethyl-Phenyl-Cyclohexanderivate |
| DE10049483A1 (de) * | 2000-09-29 | 2002-05-02 | Gruenenthal Gmbh | Substituierte 1-Aminobutan-3-ol-Derivate |
| DE10048714A1 (de) * | 2000-09-30 | 2002-04-11 | Gruenenthal Gmbh | 5-Amino-1-penlen-3-ol-Derivate |
| US6649783B2 (en) * | 2001-10-03 | 2003-11-18 | Euro-Celtique, S.A. | Synthesis of (+/-)-2-((dimethylamino)methyl)-1-(aryl)cyclohexanols |
| WO2003048113A1 (en) * | 2001-11-30 | 2003-06-12 | Sepracor Inc. | Tramadol analogs and uses thereof |
-
2000
- 2000-09-29 DE DE10049483A patent/DE10049483A1/de not_active Withdrawn
-
2001
- 2001-09-28 NZ NZ524976A patent/NZ524976A/en unknown
- 2001-09-28 JP JP2002531080A patent/JP2004509939A/ja active Pending
- 2001-09-28 WO PCT/EP2001/011231 patent/WO2002028817A1/de not_active Ceased
- 2001-09-28 HU HU0303361A patent/HUP0303361A3/hu unknown
- 2001-09-28 AR ARP010104583A patent/AR034158A1/es unknown
- 2001-09-28 KR KR1020037004490A patent/KR100835549B1/ko not_active Expired - Fee Related
- 2001-09-28 EP EP01969791A patent/EP1322592B2/de not_active Expired - Lifetime
- 2001-09-28 BR BR0114381-6A patent/BR0114381A/pt not_active IP Right Cessation
- 2001-09-28 KR KR1020037004521A patent/KR100864796B1/ko not_active Expired - Fee Related
- 2001-09-28 EP EP01985699A patent/EP1322593B1/de not_active Expired - Lifetime
- 2001-09-28 AT AT01969791T patent/ATE272045T1/de active
- 2001-09-28 WO PCT/EP2001/011276 patent/WO2002026694A1/de not_active Ceased
- 2001-09-28 CN CNA018196454A patent/CN1478067A/zh active Pending
- 2001-09-28 IL IL15510501A patent/IL155105A0/xx unknown
- 2001-09-28 AU AU2001289937A patent/AU2001289937B2/en not_active Ceased
- 2001-09-28 DK DK01985699T patent/DK1322593T3/da active
- 2001-09-28 SK SK338-2003A patent/SK3382003A3/sk not_active Application Discontinuation
- 2001-09-28 CA CA002423903A patent/CA2423903A1/en not_active Abandoned
- 2001-09-28 AT AT01985699T patent/ATE272046T1/de not_active IP Right Cessation
- 2001-09-28 TR TR2004/02030T patent/TR200402030T4/xx unknown
- 2001-09-28 HK HK03105163.7A patent/HK1052925B/zh not_active IP Right Cessation
- 2001-09-28 JP JP2002532404A patent/JP2004510755A/ja active Pending
- 2001-09-28 CA CA002423860A patent/CA2423860A1/en not_active Abandoned
- 2001-09-28 AU AU8993701A patent/AU8993701A/xx active Pending
- 2001-09-28 DE DE50103036T patent/DE50103036D1/de not_active Expired - Lifetime
- 2001-09-28 NZ NZ525171A patent/NZ525171A/en unknown
- 2001-09-28 AU AU2057802A patent/AU2057802A/xx active Pending
- 2001-09-28 SI SI200130184T patent/SI1322592T1/xx unknown
- 2001-09-28 TR TR2004/02230T patent/TR200402230T4/xx unknown
- 2001-09-28 PT PT01985699T patent/PT1322593E/pt unknown
- 2001-09-28 MX MXPA03002737A patent/MXPA03002737A/es active IP Right Grant
- 2001-09-28 HU HU0303195A patent/HUP0303195A3/hu unknown
- 2001-09-28 ES ES01969791T patent/ES2225605T5/es not_active Expired - Lifetime
- 2001-09-28 SK SK340-2003A patent/SK286727B6/sk not_active IP Right Cessation
- 2001-09-28 MX MXPA03002738A patent/MXPA03002738A/es active IP Right Grant
- 2001-09-28 BR BR0114380-8A patent/BR0114380A/pt not_active IP Right Cessation
- 2001-09-28 IL IL15510601A patent/IL155106A0/xx unknown
- 2001-09-28 RU RU2003111753/04A patent/RU2288219C2/ru not_active IP Right Cessation
- 2001-09-28 HK HK03105140.5A patent/HK1052924B/zh not_active IP Right Cessation
- 2001-09-28 SI SI200130189T patent/SI1322593T1/xx unknown
- 2001-09-28 DK DK01969791T patent/DK1322592T4/da active
- 2001-09-28 PE PE2001000968A patent/PE20020413A1/es not_active Application Discontinuation
- 2001-09-28 CN CNB018166067A patent/CN100391933C/zh not_active Expired - Fee Related
- 2001-09-28 RU RU2003111756/04A patent/RU2286334C2/ru not_active IP Right Cessation
- 2001-09-28 PL PL01361382A patent/PL361382A1/xx unknown
- 2001-09-28 AU AU2002220578A patent/AU2002220578B2/en not_active Ceased
- 2001-09-28 ES ES01985699T patent/ES2225628T3/es not_active Expired - Lifetime
- 2001-09-28 PL PL01361632A patent/PL361632A1/xx not_active Application Discontinuation
- 2001-09-28 PT PT01969791T patent/PT1322592E/pt unknown
- 2001-09-28 DE DE50103035T patent/DE50103035D1/de not_active Expired - Lifetime
-
2003
- 2003-03-26 NO NO20031387A patent/NO20031387L/no not_active Application Discontinuation
- 2003-03-26 NO NO20031382A patent/NO20031382L/no not_active Application Discontinuation
- 2003-03-28 US US10/401,020 patent/US7022739B2/en not_active Expired - Fee Related
- 2003-03-28 EC EC2003004530A patent/ECSP034530A/es unknown
- 2003-03-28 EC EC2003004532A patent/ECSP034532A/es unknown
- 2003-03-31 US US10/402,147 patent/US6828345B2/en not_active Expired - Fee Related
- 2003-04-24 ZA ZA200303220A patent/ZA200303220B/en unknown
- 2003-04-24 ZA ZA200303214A patent/ZA200303214B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034158A1 (es) | Derivados de 1-aminobutano-3-ol sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de derivados de 1-aminobutano-3-ol sustituidos para la preparacion de medicamentos | |
| AR034160A1 (es) | Sulfonilguanidinas, medicamentos que contienen estos compuestos y el uso de sulfonilguanidinas | |
| RS57533B1 (sr) | Heteroaril amidi kao inhibitori proteinske agregacije | |
| ES2885049T3 (es) | Derivados de bis-heteroarilo como moduladores de la agregación de proteínas | |
| US12168657B2 (en) | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives | |
| CO5580820A2 (es) | Derivados novedosos de acido (2s)-3-(4-{2-[amino]-2-oxoetoxi} fenil)-2-etoxipropanoico procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| JP7100043B2 (ja) | タンパク質凝集のモジュレーターとしてのビス－ヘテロアリール誘導体 | |
| PH12018500106A1 (en) | Ethynyl derivatives as metabotropic glutamate receptor modulators | |
| AR056004A1 (es) | Derivados de pirrolo[2, 3 -d]pirimidina, metodos de sintesis de los mismos y sus intermediarios de preparacion | |
| AR070398A1 (es) | Derivados sustituidos de indol | |
| JP2005527593A5 (es) | ||
| AR082994A1 (es) | Derivados de pirazina como bloqueadores del canal epitelial de sodio | |
| HRP20120505T1 (hr) | Supstituirani n fenilmetil oksoprolin amidi kao antagonisti receptora p x i postupci njihove upotrebe | |
| AR034265A1 (es) | Aminoacidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de aminoacidos para la preparacion de medicamentos para el tratamiento de dolores | |
| MX2010001080A (es) | Pirrolidin-aril-eteres como antagonistas de receptor de nk3. | |
| MA38272A1 (fr) | Peptides en tant qu'agonistes de l'oxytocine | |
| EA038090B1 (ru) | Ингибиторы magl | |
| AR034159A1 (es) | Derivados de 5-amino-1-penten-3-ol sustituidos, procedimiento para su preparacion, medicamentos que contienen estos derivados y su uso para la preparacion de medicamentos | |
| JPWO2020198466A5 (es) | ||
| AR110122A1 (es) | Fenoxitriazoles | |
| HRP20201473T1 (hr) | Inhibitori lizin gingipaina | |
| AR054557A1 (es) | Tienopirimidinonas, tienopiridazinonas y tienotriazinonas para el tratamiento de obesidad | |
| AR070885A1 (es) | Compuestos de azaindol para el tratamiento de trastornos del sistema nervioso central | |
| JP2020500215A5 (es) | ||
| EP4482823A1 (en) | Di-cyclopropyl based il-17a modulators and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |